

10/6/2021

Vermont Attorney General's Office

109 State Street

Montpelier, VT 05609

AGO.highcostprescriptiondrugs@vermont.gov

To Whom It May Concern:

As required by 18 V.S.A. § 4637(b), Incyte Corporation is providing notice of the introduction of a new prescription drug with a Wholesale Acquisition Cost that exceeds the threshold set for a specialty drug under the Medicare Part D program on October 4, 2021. The new product being launched is:

Opzelura (ruxolitinib) cream 1.5% 60gm tube: 50881-0007-05

Sincerely,

John Whitridge

Consultant